A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients

Leukemia & Lymphoma
P GossD Sutton

Abstract

This phase II study was designed to improve the outcome of elderly patients with advanced aggressive non-Hodgkin's lymphomas (NHL's) by employing a novel chemotherapy regimen PEN (prednisone, oral etoposide and mitoxantrone), as initial treatment. Between July 1991 and September 1993, 43 patients (14 male, 29 female) aged 66-82 years (median 74) received 1-8 (median 4) courses of PEN (total 192) q28 days (prednisone 50 mg od x 14 days, oral etoposide 50 mg od x 14 days and mitoxantrone 8 mg/m2 i.v. day 1) in the ambulatory setting. Pathologies of patients' tumors classified by the Working Formulation (WF) included C = 4, D = 2, E = 1, F = 7, G = 25, H = 4. Eighteen patients (42%) had stage IV, 15 (35%) stage III, 9 (21%) stage II and 1 (2%) stage I disease. Nineteen patients (44%) had B symptoms, 7 (16%) primarily extranodal disease and 15 (35%) bone marrow involvement. Patients with congestive heart failure, current anti-failure medication or pretreatment Muga left ventricular ejection fraction (LVEF) of < 45% (median pretreatment 60%) were excluded from PEN. After a median follow-up of 8.5 months (range 1-30), 14 of 33 evaluable patients (42%) have achieved CR of their disease for 8+ months (range 4-19) and 6 (18%) PR for 6+ ...Continue Reading

References

Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Dec 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L SalvagnoM V Fiorentino
Mar 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S PavlovskyH Magnasco
May 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E O'ReillyJ M Connors
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U TirelliS Monfardini
Feb 1, 1992·Southern Medical Journal·L Williams, D T Lowenthal
Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseJ Mailliard
Jan 1, 1989·Leukemia Research·E A StadtmauerR P Gale
Nov 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U TirelliW P Breed
Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B J Kennedy
Jan 1, 1986·CA: a Cancer Journal for Clinicians·A Baranovsky, M H Myers
Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D O DixonH E Wilson
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MartelliF Mandelli
Jun 1, 1993·Leukemia & Lymphoma·P E Goss
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E O'ReillyD S Stuart

❮ Previous
Next ❯

Citations

Mar 29, 2000·Critical Reviews in Oncology/hematology·S M Lichtman
Apr 30, 1999·Leukemia & Lymphoma·F P PetersH C Schouten
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J K DoorduijnP Sonneveld
Jun 14, 2018·The Oncologist·Haige YeMichael L Wang
Nov 20, 1998·Hematological Oncology·U TirelliS Monfardini
Mar 23, 2010·Critical Reviews in Oncology/hematology·A GutiérrezJ Rodríguez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.